Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2012 1
2014 3
2015 2
2018 2
2019 1
2020 5
2021 4
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for shaozhang zhou
Search for Sanzhang Zhou instead (1 results)
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Tang X, Yu J, Maher E, Feng H, Yao S, Keegan P, Wang J. Wang Z, et al. Among authors: zhou s. J Clin Oncol. 2023 Jan 20;41(3):651-663. doi: 10.1200/JCO.22.00727. Epub 2022 Oct 7. J Clin Oncol. 2023. PMID: 36206498 Free PMC article. Clinical Trial.
The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
Chen S, Mo W, Jiang W, Zhou S, Gan H, Yu Q. Chen S, et al. Among authors: zhou s. Front Immunol. 2023 Aug 8;14:1218258. doi: 10.3389/fimmu.2023.1218258. eCollection 2023. Front Immunol. 2023. PMID: 37614237 Free PMC article.
The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis.
Zhao Y, He J, Zhou S, Ning R, Zhao W, Wang H, Su C, Jiang W, Zhong X, Yu Q. Zhao Y, et al. Among authors: zhou s. Comput Math Methods Med. 2022 Sep 7;2022:1679191. doi: 10.1155/2022/1679191. eCollection 2022. Comput Math Methods Med. 2022. PMID: 36118825 Free PMC article.
Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy.
Yuan C, Huang M, Wang H, Jiang W, Su C, Zhou S. Yuan C, et al. Among authors: zhou s. Cancer Manag Res. 2022 Jan 26;14:377-386. doi: 10.2147/CMAR.S347547. eCollection 2022. Cancer Manag Res. 2022. PMID: 35115834 Free PMC article.
PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
Chen S, Wei H, Zhao W, Jiang W, Ning R, Zhou S, Tan L, Wang H, Su C, He J, Zeng A, Zhao Y, Yu Q. Chen S, et al. Among authors: zhou s. Front Immunol. 2022 Dec 7;13:1059995. doi: 10.3389/fimmu.2022.1059995. eCollection 2022. Front Immunol. 2022. PMID: 36569915 Free PMC article.
28 results